NCT04998578

Brief Summary

The microneedle is a minimally invasive technique, consists of the application of a roller surrounded by small and thin needles that pierce the skin and generate a mechanical stimulus with no ablative effect on the skin. The study aims to test the hypothesis that the technique of microneedle in the treatment of tissue flaccidity and hyperchromia of female external genitalia is safe and with a more effective result in clinical improvement through genital rejuvenation and unification of skin tone when compared to non-ablative radiofrequency technique.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
112

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2021

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 26, 2019

Completed
2.1 years until next milestone

First Posted

Study publicly available on registry

August 10, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

October 1, 2021

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2024

Completed
Last Updated

December 11, 2023

Status Verified

December 1, 2023

Enrollment Period

3 years

First QC Date

June 26, 2019

Last Update Submit

December 4, 2023

Conditions

Keywords

microneedlinglaxitySkin Hyperpigmentation

Outcome Measures

Primary Outcomes (2)

  • External genital Laxity

    It will be evaluated by turgor, number of skinfolds, evidenced by self report, comparison of images taken before and after the procedure and satisfaction of the patient, verified in the Likert scale and Visual Analog Scale.

    1, 3, 6 and 12 months after treatment

  • Genital Hyperchromia

    It will be evaluated the uniformity of the skin tone, evidenced by the self report, comparison of images taken before after the procedure and satisfaction of the participant, verified in the scale of Likert and Scale Visual Analog.

    1, 3, 6 and 12 months after treatment

Secondary Outcomes (3)

  • Sexual function

    1, 3, 6 and 12 months after treatment

  • Female Genital Self-Image

    1, 3, 6 and 12 months after treatment

  • Melasma Quality of Life

    1, 3, 6 and 12 months after treatment

Study Arms (4)

Microneedling- Group A

ACTIVE COMPARATOR

Participants will only perform microneedling

Device: Comparison of aesthetic techniques

Microneedling and outpatient Cosmetics- Group B

ACTIVE COMPARATOR

Microneedling associated with the use of outpatient cosmetics

Device: Comparison of aesthetic techniques

microneedling and home use cosmetics - Group C

ACTIVE COMPARATOR

Microneedling associated with home use cosmetics

Device: Comparison of aesthetic techniques

Non-ablative radiofrequency - Group D

ACTIVE COMPARATOR

Participants will perform only non-ablative radiofrequency

Device: Comparison of aesthetic techniques

Interventions

Comparison of aesthetic techniques for rejuvenation and glazing of the genital region

Microneedling and outpatient Cosmetics- Group BMicroneedling- Group ANon-ablative radiofrequency - Group Dmicroneedling and home use cosmetics - Group C

Eligibility Criteria

Age18 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women aged 18-65 years with skin flaccidity and genital hyperchromia

You may not qualify if:

  • Patients who use cosmetics in the genital region
  • Use of anticoagulant medication
  • Use of pacemakers
  • Pregnancy
  • Dermatoses in the region to be treated and / or local inflammatory condition, without diagnosis of infection
  • Difficulty in understanding the proposed instruments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Centro de Atenção ao Assoalho Pelvico

Salvador, Estado de Bahia, 40.290-000, Brazil

RECRUITING

Centro de Atenção ao assoalho pélvico

Salvador, Estado de Bahia, 40290000, Brazil

RECRUITING

Related Publications (18)

  • Vieira-Baptista P, Marchitelli C, Haefner HK, Donders G, Perez-Lopez F. Deconstructing the genitourinary syndrome of menopause. Int Urogynecol J. 2017 May;28(5):675-679. doi: 10.1007/s00192-017-3295-6. Epub 2017 Mar 14.

    PMID: 28293790BACKGROUND
  • Marnach ML, Torgerson RR. Vulvovaginal Issues in Mature Women. Mayo Clin Proc. 2017 Mar;92(3):449-454. doi: 10.1016/j.mayocp.2016.10.031.

    PMID: 28259230BACKGROUND
  • Filippini M, Del Duca E, Negosanti F, Bonciani D, Negosanti L, Sannino M, Cannarozzo G, Nistico SP. Fractional CO2 Laser: From Skin Rejuvenation to Vulvo-Vaginal Reshaping. Photomed Laser Surg. 2017 Mar;35(3):171-175. doi: 10.1089/pho.2016.4173. Epub 2016 Dec 30.

    PMID: 28056209BACKGROUND
  • Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014 Oct;21(10):1063-8. doi: 10.1097/GME.0000000000000329.

    PMID: 25160739BACKGROUND
  • Lapii GA, Yakovleva AY, Neimark AI. Structural Reorganization of the Vaginal Mucosa in Stress Urinary Incontinence under Conditions of Er:YAG Laser Treatment. Bull Exp Biol Med. 2017 Feb;162(4):510-514. doi: 10.1007/s10517-017-3650-0. Epub 2017 Feb 27.

    PMID: 28243906BACKGROUND
  • Ho D, Kraeva E, Wun T, Isseroff RR, Jagdeo J. A single-blind, dose escalation, phase I study of high-fluence light-emitting diode-red light (LED-RL) on human skin: study protocol for a randomized controlled trial. Trials. 2016 Aug 2;17:385. doi: 10.1186/s13063-016-1518-7.

    PMID: 27484782BACKGROUND
  • Miyata S, Miyaji H, Kawasaki H, Yamamoto M, Nishida E, Takita H, Akasaka T, Ushijima N, Iwanaga T, Sugaya T. Antimicrobial photodynamic activity and cytocompatibility of Au25(Capt)18 clusters photoexcited by blue LED light irradiation. Int J Nanomedicine. 2017 Apr 4;12:2703-2716. doi: 10.2147/IJN.S131602. eCollection 2017.

    PMID: 28435253BACKGROUND
  • Takada A, Matsushita K, Horioka S, Furuichi Y, Sumi Y. Bactericidal effects of 310 nm ultraviolet light-emitting diode irradiation on oral bacteria. BMC Oral Health. 2017 Jun 6;17(1):96. doi: 10.1186/s12903-017-0382-5.

    PMID: 28587675BACKGROUND
  • Arunkalaivanan A, Kaur H, Onuma O. Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J. 2017 May;28(5):681-685. doi: 10.1007/s00192-017-3282-y. Epub 2017 Feb 2.

    PMID: 28154914BACKGROUND
  • Nilsson K, Risberg B, Heimer G. The vaginal epithelium in the postmenopause--cytology, histology and pH as methods of assessment. Maturitas. 1995 Jan;21(1):51-6. doi: 10.1016/0378-5122(94)00863-3.

    PMID: 7731384BACKGROUND
  • Flores SA, Hall CA. Atrophic Vaginitis(Archived). 2025 Jun 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK564341/

    PMID: 33232011BACKGROUND
  • Herbenick D, Reece M. Development and validation of the female genital self-image scale. J Sex Med. 2010 May;7(5):1822-30. doi: 10.1111/j.1743-6109.2010.01728.x. Epub 2010 Mar 3.

    PMID: 20233278BACKGROUND
  • Cain JM, Iglesia CB, Dickens B, Montgomery O. Body enhancement through female genital cosmetic surgery creates ethical and rights dilemmas. Int J Gynaecol Obstet. 2013 Aug;122(2):169-72. doi: 10.1016/j.ijgo.2013.03.020. Epub 2013 Jun 2.

    PMID: 23735570BACKGROUND
  • McPencow AM, Guess MK. Giving female genital cosmetic surgery a facelift. Maturitas. 2012 Apr;71(4):313-4. doi: 10.1016/j.maturitas.2012.01.012. Epub 2012 Feb 14. No abstract available.

    PMID: 22341089BACKGROUND
  • Doddaballapur S. Microneedling with dermaroller. J Cutan Aesthet Surg. 2009 Jul;2(2):110-1. doi: 10.4103/0974-2077.58529.

    PMID: 20808602BACKGROUND
  • Ramaut L, Hoeksema H, Pirayesh A, Stillaert F, Monstrey S. Microneedling: Where do we stand now? A systematic review of the literature. J Plast Reconstr Aesthet Surg. 2018 Jan;71(1):1-14. doi: 10.1016/j.bjps.2017.06.006. Epub 2017 Jun 17.

    PMID: 28690124BACKGROUND
  • Fabbrocini G, De Vita V, Fardella N, Pastore F, Annunziata MC, Mauriello MC, Monfrecola A, Cameli N. Skin needling to enhance depigmenting serum penetration in the treatment of melasma. Plast Surg Int. 2011;2011:158241. doi: 10.1155/2011/158241. Epub 2011 Apr 7.

    PMID: 22567235BACKGROUND
  • Goodman MP. Female genital cosmetic and plastic surgery: a review. J Sex Med. 2011 Jun;8(6):1813-25. doi: 10.1111/j.1743-6109.2011.02254.x. Epub 2011 Apr 14.

    PMID: 21492397BACKGROUND

MeSH Terms

Conditions

Cutis LaxaHyperpigmentation

Condition Hierarchy (Ancestors)

Skin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesConnective Tissue DiseasesSkin and Connective Tissue DiseasesSkin DiseasesPigmentation Disorders

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Masking Details
the data of the participants will be collected by evaluators blind to the study and who will not know the allocation of the patients
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Group A will only perform microneedling; group B will perform microneedling associated with the use of cosmetic in the office; group C will perform microneedling associated with the cosmetology of office and home use; and group D will perform non-ablative radiofrequency. Due to the application characteristics of the microneedle technique, there is no way to use a placebo group.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 26, 2019

First Posted

August 10, 2021

Study Start

October 1, 2021

Primary Completion

October 1, 2024

Study Completion

October 1, 2024

Last Updated

December 11, 2023

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

Locations